MDM2/MDMX inhibitors/antagonists

Isoform-selective Products

Cat.No. Product Name Information Product Use Citations Product Validations
S1061 Nutlin-3 Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with an IC50 of 90 nM in a cell-free assay; it stabilises p73 in p53-deficient cells.
Cancer Discov, 2025, 15(1):69-82
iScience, 2025, 28(6):112635
Biomed Rep, 2025, 22(4):65
Verified customer review of Nutlin-3
S7030 RG-7112 RG7112 (RO5045337) is an orally bioavailable and selective p53-MDM2 inhibitor with HTRF IC50 of 18 nM.
NPJ Aging, 2025, 11(1):6
Int J Mol Sci, 2024, 25(7)3948
bioRxiv, 2024, 2024.10.09.617493
S8059 Nutlin-3a Nutlin-3a ((-)-Nutlin-3), the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner.
Nucleic Acids Res, 2025, 53(13)gkaf627
Cell Rep Med, 2025, 6(8):102284
Bone Res, 2025, 13(1):62
Verified customer review of Nutlin-3a
E1491 Brigimadlin Brigimadlin (BI 907828) is a potent, orally active inhibitor of E3 ubiquitin-protein ligase MDM-2. This compound inhibits MDM-2's suppression of the tumour suppressor p53. It promotes Apoptosis and enhances the transcription of p53 targets such as p21 and PUMA in BT48, BT67, and BT73 cells.
S3604 Triptolide Triptolide is a diterpene triepoxide, an immunosuppressive agent extracted from the Chinese herb Tripterygium wilfordii. It functions as a NF-κB inhibitor with dual actions by disruption of p65/CBP interaction and by reduction of p65 protein. Triptolide (PG490) abrogates the transactivation function of heat shock transcription factor 1 (HSF1). Triptolide inhibits MDM2 and induces apoptosis through a p53-independent pathway.
Mol Cell, 2025, S1097-2765(25)00316-8
Mol Cell, 2025, 85(15):2839-2853.e8
Chin Med, 2025, 20(1):122
Verified customer review of Triptolide
S7205 Idasanutlin (RG7388) Idasanutlin (RG7388) is a potent and selective p53-MDM2 inhibitor with an IC50 of 6 nM, and it shows improved in vitro binding as well as cellular potency/selectivity.
Nat Commun, 2025, 16(1):2229
Leukemia, 2025, 39(12):2881-2894
Cancer Res, 2025, 10.1158/0008-5472.CAN-24-1136
S7649 SAR405838 SAR405838 is an orally available MDM2 antagonist with Ki of 0.88 nM. This compound is a diastereomer of MI-773 (CAS: 1303607-07-9). Phase 1.
Nat Genet, 2025, 57(1):140-153
Pharmaceutics, 2023, 15(4)1274
bioRxiv, 2023, 10.1101/2023.03.10.531074
Verified customer review of SAR405838
S2678 NSC 207895 NSC 207895 (XI-006) suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.
PLoS One, 2024, 19(1):e0295629
Front Oncol, 2021, 11:582511
Genes Dev, 2020, 34(7-8):526-543
Verified customer review of NSC 207895
S7875 NVP-CGM097 NVP-CGM097 is a highly potent and selective MDM2 inhibitor with Ki value of 1.3 nM for hMDM2 in TR-FRET assay. It binds to the p53 binding-site of the Mdm2 protein, disrupting the interaction between both proteins, leading to an activation of the p53 pathway.
Haematologica, 2022, 10.3324/haematol.2022.280879
Cell Death Dis, 2021, 12(1):98
Eur J Cancer, 2020, 126:93-103
Verified customer review of NVP-CGM097
S8606 Siremadlin (HDM201) Siremadlin (HDM201) is a novel, highly potent and selective inhibitor of the p53-Mdm2 interaction, with an affinity constant for MDM2 in the picomolar range and a selectivity ratio greater than 10000-fold vs MDM4.
J Exp Clin Cancer Res, 2023, 42(1):9
BMC Cancer, 2023, 23(1):47
Cell Genom, 2023, 3(7):100321